



Dr. Peng is a PhD in pharmacology and toxicology at Beijing Institute of Pharmacology and Toxicology, a postdoctoral fellow in public health at Peking University and postdoctoral fellow in pharmacology at Michigan State University. Dr. Peng is a chief scientist officer at Shanghai Medicilon Inc. Dr. Peng is the President of Committee of Toxicological Alternatives and Translational Toxicology Chinese Society of Toxicology (CSOT) from 2014-2024, and the President of Committee of Toxicity Testing and Alternatives, Chinese Environmental Mutagen Society (CEMS), and vice president of CEMS. Dr. Peng led the development and application of animal-free testing methods in regulatory toxicology in China, and as chairman of the conference, organized eight International Conference on Toxicological Alternatives & Translational Toxicology in China. He has been engaged in pre-clinical research of new drug innovation, food safety evaluation and chemical risk assessment for more than 30 years, and has undertaken the construction of national GLP technology platform. Dr. Peng presided over and undertook more than 40 national scientific projects, including 973 Project, 863 Plan and the national “New Drug Development and Innovation Project”. He has published more than 300 scientific research papers and edited 13 monographs. Dr. Peng won 12 scientific and technological achievement awards. He has received the special government allowance of the State Council, the honorary title of national Outstanding Scientific and Technological Worker” by the China Association for Science and Technology, and the Outstanding Contribution Award of Chinese Toxicology. Dr. Peng has trained more than 90 masters, doctoral and postdoctoral students. He holds academic positions such as new drug review experts and medical device review experts of NMPA, new chemical substance review experts of the Ministry of Ecology and Environment, and the ETAP deputy editor-in –chief.